Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded at StockNews.com

StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP – Free Report) from a hold rating to a buy rating in a research note issued to investors on Tuesday. Separately, HC Wainwright restated a neutral rating on shares of Oramed Pharmaceuticals in a research note on Monday, May 20th. Get Our Latest Stock Report on ORMP Oramed […]

Leave a Reply

Your email address will not be published.

Previous post Brokerages Set Jack Henry & Associates, Inc. (NASDAQ:JKHY) Price Target at $176.45
Next post Coterra Energy Inc. (NYSE:CTRA) Receives $33.56 Consensus Price Target from Analysts